दवाओं की अंतःक्रिया
Amivantamab + Lazertinib
गंभीरता: मध्यम
Amivantamab and Lazertinib: moderate interaction.
अंतिम अपडेट
केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।
इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।
सारांश
Amivantamab with lazertinib raises the risk of venous thromboembolism, and prophylaxis is recommended. Vitamin K antagonists are poorly suited for this because their variable effect makes control difficult, whereas the interaction concerns the combination's thrombotic risk.
इस इंटरैक्शन का सरल भाषा में अर्थ
Amivantamab and Lazertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Amivantamab belongs to Oncology; Lazertinib belongs to Oncology.
ऐसा क्यों होता है
The combination increases thromboembolic risk by an incompletely established mechanism.
क्या करें
Give anticoagulant prophylaxis during the first months of therapy, preferably with a direct oral anticoagulant or low molecular weight heparin rather than a vitamin K antagonist. Monitor for signs of VTE.
फार्मासिस्ट से क्या पूछें
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ सदस्यों के लिए
पूरा पेज खोलें
Amivantamab और Lazertinib की पूरी प्रबंधन सलाह, अतिरिक्त नोट्स, साक्ष्य का विवरण और पूरे पर्चे का इंटरैक्शन चेकर खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें।
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
वेब पर Pro+ को 14 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।
अक्सर पूछे जाने वाले प्रश्न
Can I take Amivantamab with Lazertinib?
MediHelp rates the interaction as moderate. Amivantamab and Lazertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Amivantamab with lazertinib raises the risk of venous thromboembolism, and prophylaxis is recommended. Vitamin K antagonists are poorly suited for this because their variable effect makes control difficult, whereas the interaction concerns the combination's thrombotic risk.
How serious is the interaction between Amivantamab and Lazertinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Give anticoagulant prophylaxis during the first months of therapy, preferably with a direct oral anticoagulant or low molecular weight heparin rather than a vitamin K antagonist. Monitor for signs of VTE.
MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर
MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।
